Publications
Fitusiran Reaches People's with Hemophilia and Their Caregivers’ Treatment Expectations: Qualitative Semi-Structured Interviews of Participants of ATLAS-OLE Trial (Interim analysis)
Alok Srivastava, Savita Rangarajan, Cecil Ross, Christina Slota, Dana DiBenedetti, Viridiana Cano, Shauna Andersson, Pronabesh Dasmahapatra, José Bartelt-Hofer, Marion Afonso Crossmark: Check for Updates Abstract
Background: Current prophylaxis treatments for people with hemophilia A and B can be burdensome, involving frequent intravenous or subcutaneous doses in addition to on demand treatments due to breakthrough bleeds. Fitusiran is an, investigational, subcutaneously administered small interfering RNA therapy, meant to improve thrombin generation, restore hemostasis, and prevent bleeding in all people with hemophilia. Fitusiran has been evaluated in three phase 3 trials: two completed randomized phase 3 clinical trials (ATLAS-INH and ATLAS-A/B), and one phase 3 "switching” study (ATLAS-PPX). Individuals completing any of these 3 parent studies were eligible for the open-label extension study (ATLAS-OLE), which is currently ongoing.